External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised studyM. Bolla, Laurence Collette, José Lopez Torecilla et al.|The Lancet Oncology|2010Cited by 944
Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progressionSujun Chen, Shancheng Ren, Guanghui Zhu et al.|Nature Cell Biology|2021Cited by 537
Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical OutcomeBas W.G. van Rhijn, Ellen C. Zwarthoff, André N. Vis et al.|Journal of Clinical Oncology|2003Cited by 321
FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and TherapyLucie C. Kompier, Ellen C. Zwarthoff, Irene Lurkin et al.|PLoS ONE|2010Cited by 314
The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate.Bas W.G. van Rhijn, Ellen C. Zwarthoff, Irene Lurkin et al.|PubMed|2001Cited by 309